Clinical Pharmacology of Senile Dementia

Abstract

This review analyzes the efficacy and limitations of pharmacological agents used in the treatment of senile dementia. Methodological flaws in clinical studies—including small sample sizes, heterogeneous patient populations, short trial durations, and lack of placebo control—have complicated the interpretation of drug effectiveness. Most vasodilators, nootropic agents, neurotransmitter precursors, and neuropeptides have shown no significant benefit beyond placebo. However, compounds such as hydergine and vasopressin have demonstrated limited therapeutic potential. Advances in neurochemical research related to Alzheimer’s disease and dementia offer promising avenues for developing more effective treatments.

Keywords

• demans
• klinik
• farmakoloji

Senil Demansın Klinik Farmakolojisi

Abstract

Bu derleme, senil demansın tedavisinde kullanılan farmakolojik ajanların etkinliğini ve klinik kullanımdaki sınırlılıklarını ele almaktadır. Literatürdeki çalışmalarda yer alan metodolojik hatalar — düşük hasta sayısı, heterojen vaka grupları, kısa süreli denemeler ve plasebo kontrol eksiklikleri — ilaca dayalı tedavilerin yorumlanmasını güçleştirmektedir. Vazodilatörler, nootropik ajanlar, nörotransmitter öncüleri ve nöropeptidlerin birçoğunun plasebodan üstün olmadığı saptanmış; yalnızca hiderjin ve vazopressin gibi bazı bileşikler sınırlı fayda göstermiştir. Alzheimer hastalığı ve demansla ilişkili nörokimyasal bozukluklar üzerine yapılan araştırmalar, etkili tedavi geliştirme yolunda umut vermektedir.

Keywords

• demans
• klinik
• farmakoloji

References

1. 1. Ron, M.A., Toone, B.K., Garralda, M.E., Lishman, W.A. — Diagnostic accuracy in presenile dementia. *Br. J. Psychiat.*, 134: 161–168, 1979.
2. 2. Branconnier, R.J., Cole, J.O. — Effect of chronic papaverine administration on mild senile organic brain syndrome. *J. Am. Geriatr. Soc.*, 25: 458–462, 1977.
3. 3. Tomlinson, B.E., Blessed, G., Roth, M. — Observations on the brains of demented old people. *J. Neurol. Sci.*, 11: 205–242, 1970.
4. 4. Meier Ruge, W., Iwangoff, P., Reichlmeier, K., Sandoz, P. — Neurochemical findings in aging brain. In: *Ergot Compounds and Brain Function*, Ed. M. Goldstein, Raven Press, New York, pp. 323–338, 1980.
5. 5. Spagloni, A., Tognoni, G. — Ergot alkaloids. In: *Drug Treatment and Prevention in Cerebrovascular Disorders*, Eds. G. Tognoni, S. Garattini, Elsevier/North Holland, Amsterdam, pp. 223–233, 1979.
6. 6. Loew, D.M., Vigouret, J.M., Jaton, A.L. — Ergot derivatives and the central nervous system: Effects of codergocrine mesylate on central synaptic transmission. In: *Geriatric Psychopharmacology*, Ed. K. Nendy, Elsevier/North Holland, Amsterdam, pp. 173–193, 1979.
7. 7. Hughes, J.R., Williams, J.G., Currier, R.D. — An ergot alkaloid preparation (Hydergine) in the treatment of dementia: Critical review of the clinical literature. *Am. Geriat. Soc.*, 24: 490–497, 1976.
8. 8. Soni, S.D., Soni, S.S. — Dehydrogenated alkaloids of ergotoxine in nonhospitalized elderly patients. *Curr. Med. Res. Opin.*, 3: 464–468, 1975.

9. 9. Brodie, N.H. — A double-blind trial of Naftidrofuryl in treating confused elderly patients in general practice. *Practitioner*, 218: 274–278, 1977.
10. 10. Cox, J.R. — Double-blind evaluation of Naftidrofuryl in treating elderly confused hospitalized patients. *Geront. Clin.*, 17: 160–167, 1975.
11. 11. Judge, T.G., Urquhart, A. — Naftidrofuryl—a double-blind crossover study in the elderly. *Curr. Therap. Res.*, 17: 166–172, 1972.
12. 12. Abuzzahab, F.S., Mervin, G.E., Zimmerman, R.C., Sherman, M.C. — A double-blind investigation of piracetam (Nootropil) versus placebo in the memory of geriatric inpatients. *Psychopharmacol. Bull.*, 14: 23–25, 1978.
13. 13. Stegink, A.J. — The clinical use of piracetam, a new nootropic drug. The treatment of symptoms of senile involution. *Arzheim. Forsch.*, 22: 975–977, 1972.
14. 14. Davies, P., Maloney, A.J.F. — Selective loss of central cholinergic neurons in Alzheimer's Disease. *Lancet*, 2: 1403, 1976.
15. 15. Davies, P., Verth, A.H. — Regional distribution of muscarinic acetylcholine receptors in normal and Alzheimer type dementia brains. *Brain Res.*, 138: 385–392, 1978.
16. 16. Ferris, S.H., Sathananthan, G., Gershon, S., Clark, C. — Senile dementia: Treatment with deanol. *J. Am. Geriat. Soc.*, 25: 241–244, 1977.
17. 17. Cohen, E.L., Wurtman, R.J. — Brain acetylcholine: Control by dietary choline. *Science*, 191: 561–562, 1976.
18. 18. Johnson, K., Presley, A.S., Ballinger, B.R. — Levodopa in senile dementia. *Br. Med. J.*, 1: 1625, 1978.
19. 19. Meyer, J.S., Welch, K.M.A., Deshmukh, V.D., Perez, F.I., Jacob, R.H., Haufrecht, D.B., Mathew, N.T., Morrell, R.M. — Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer’s Disease. *J. Am. Geriat. Soc.*, 35: 289–298, 1977.
20. 20. Branconnier, R.J., Cole, J.O., Gardos, G. — ACTH₄₋₁₀ in the amelioration of neuropsychological symptomatology with senile organic brain syndrome. *Psychopharmacol. Bull.*, 14: 27–30, 1978.
21. 21. Weingartner, H., Gold, P., Ballenger, J.C., Smallberg, S.A., Summers, R., Rubinow, D.R., Post, R.M., Goodwin, F.K. — Effect of vasopressin on human memory function. *Science*, 211: 601–602, 1981.
22. 22. Davies, P., Katzman, R., Terry, R.D. — Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer's Disease senile dementia. *Nature*, 288: 279–280, 1980.